Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report
- 122 Downloads
A 50-year-old man with type II diabetes, hypertension and dyslipidemia, presented with non-oliguric acute kidney injury (AKI) and anemia. Renal biopsy showed acute tubular necrosis (ATN) with extensive cytoplasmic vacuolization and areas of tubulitis. These findings were ultimately attributed to dapagliflozin, which he started 3 months earlier due to poor glycemic control. ATN with similar microscopic findings has been described with larger doses of dapagliflozin in non-clinical trials. Our patient was started on dialysis and remained dialysis-dependent for 4 weeks while his renal function improved gradually thereafter. Sixteen months after initial presentation he is being followed as an outpatient with chronic kidney disease (CKD) stage 3a. Dapagliflozin belongs to a novel class of antidiabetic drugs for which clinical trials show great beneficial effects on cardiovascular outcomes and glycemic control and as with many new drugs, their safety profile is being constantly revised. We report the first biopsy-proven ATN caused by dapagliflozin. Great caution together with continuous monitoring of renal function is advised when implementing SGLT-2 inhibitors in clinical practice.
KeywordsAcute tubular necrosis (ATN) Dapagliflozin SGLT-2 inhibitors Diabetes
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of interest exists.
Research involving human participants and/or animals
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 1.CANVAS—CANagliflozin cardio Vascular Assessment Study (CANVAS). https://clinicaltrials.gov/ct2/show/NCT01032629?term=NCT01989754&rank=2.
- 2.Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534?term=NCT01730534&rank=1.
- 3.Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). https://clinicaltrials.gov/ct2/show/NCT01986881?term=NCT01986881&rank=1.
- 10.FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [06-14-2016] http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm.
- 12.Agati D’, Jennette VD, Silva JC. FG. Non-neoplastic kidney diseases. Silver Spring: ARP Press; 2005. pp. 517–31.Google Scholar